Alimera Sciences, Inc. (NASDAQ:ALIM) SVP Philip Ashman sold 25,500 shares of the stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $1.20, for a total transaction of $30,600.00. Following the completion of the sale, the senior vice president now owns 12,750 shares of the company’s stock, valued at approximately $15,300. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Philip Ashman also recently made the following trade(s):

  • On Wednesday, January 17th, Philip Ashman sold 25,500 shares of Alimera Sciences stock. The shares were sold at an average price of $1.23, for a total transaction of $31,365.00.

Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) traded down $0.04 during midday trading on Friday, hitting $1.20. 329,291 shares of the stock were exchanged, compared to its average volume of 180,769. The firm has a market cap of $82.98, a P/E ratio of -3.87 and a beta of 2.15. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65. Alimera Sciences, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $1.72.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. equities research analysts forecast that Alimera Sciences, Inc. will post -0.27 earnings per share for the current fiscal year.

ALIM has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a report on Wednesday, November 22nd. Cowen restated a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Finally, ValuEngine upgraded shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $3.38.

A hedge fund recently raised its stake in Alimera Sciences stock. PNC Financial Services Group Inc. lifted its position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 180,300 shares of the biopharmaceutical company’s stock after buying an additional 35,200 shares during the period. PNC Financial Services Group Inc. owned approximately 0.28% of Alimera Sciences worth $251,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 41.78% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/01/19/alimera-sciences-inc-alim-svp-sells-30600-00-in-stock.html.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.